Janus kinase (JAK) inhibitors are disease-modifying agents with efficacy in treating a
spectrum of burdensome dermatologic conditions. The US Food and Drug Administration …

Baricitinib is an oral, selective inhibitor of Janus kinase (JAK) 1/JAK2 that transiently and
reversibly inhibits many proinflammatory cytokines. This mechanism is a key mediator in a …

With the increasing number of options for the treatment of moderate‐to‐severe atopic
dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent …

Abstract Introduction Baricitinib, a Janus kinase (JAK) 1/2 inhibitor, is an approved treatment
for rheumatoid arthritis (RA), atopic dermatitis (AD), and alopecia areata (AA). Further …

Background Atopic dermatitis (AD) is associated with immunological dysfunction, which may
influence cancer development. Previous studies of AD and cancer demonstrate inconsistent …

Importance Since the increased use of dupilumab for atopic dermatitis (AD) in daily practice,
several cases have been reported on the development of cutaneous T-cell lymphomas …

Abstract Background Baricitinib, a selective Janus kinase (JAK) 1/JAK2 inhibitor, is
approved for treatment of moderate-to-severe atopic dermatitis (AD) in adults. Objectives We …

Atopic dermatitis (AD) is a common, chronic and relapsing inflammatory skin disease with
various clinical presentations and combinations of symptoms. The pathophysiology of AD is …

The majority of registry studies on atopic dermatitis include only patients and diagnoses from
specialized healthcare. The aim of this retrospective, real-world cohort study was to evaluate …

The impact of new and emerging therapies on the microenvironment of primary cutaneous
lymphomas (PCLs) has been recently raised in the literature. Concomitantly, novel …